{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:03:38Z","timestamp":1793815418501,"version":"4.6.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.pharmthera.2020.107628","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T02:10:32Z","timestamp":1594260632000},"page":"107628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities"],"prefix":"10.1016","volume":"215","author":[{"given":"James Jiqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Edin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"Zeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107628_bb0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/cid\/ciu226","article-title":"Middle East respiratory syndrome coronavirus: A case-control study of hospitalized patients","volume":"59","author":"Al-Tawfiq","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M13-2486","article-title":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection","volume":"160","author":"Arabi","year":"2014","journal-title":"Annals of Internal Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107628_bb0015","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0020","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2008457","article-title":"Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility","volume":"382","author":"Arons","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12989-015-0094-4","article-title":"Acute and subchronic exposure to air particulate matter induces expression of angiotensin and bradykinin-related genes in the lungs and heart: Angiotensin-II type-I receptor as a molecular target of particulate matter exposure","volume":"12","author":"Aztatzi-Aguilar","year":"2015","journal-title":"Particle and Fibre Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1282","article-title":"Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers","author":"Bavishi","year":"2020","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2018.15","article-title":"Angiotensin-converting enzyme in innate and adaptive immunity","volume":"14","author":"Bernstein","year":"2018","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: Immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0045","doi-asserted-by":"crossref","first-page":"110491","DOI":"10.1016\/j.ecoenv.2020.110491","article-title":"Fine particulate matter increases airway hyperresponsiveness through kallikrein-bradykinin pathway","volume":"195","author":"Cao","year":"2020","journal-title":"Ecotoxicology and Environmental Safety"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/v10020093","article-title":"MERS-CoV: Understanding the latest human coronavirus threat","volume":"10","author":"Chafekar","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.0000255925.01707.eb","article-title":"Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity","volume":"49","author":"Chao","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2017.10.119","article-title":"Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy","volume":"494","author":"Chen","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.bbadis.2019.01.020","article-title":"Nrf2 deficiency aggravates angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6\/STAT3-dependent inflammation","volume":"1865","author":"Chen","year":"2019","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0075","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","article-title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2","volume":"116","author":"Chen","year":"2020","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2020.06.002","article-title":"Cardiac injuries in coronavirus disease 2019 (COVID-19)","volume":"145","author":"Chen","year":"2020","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0090","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehaa409","article-title":"Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era","volume":"41","author":"De Rosa","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nature Reviews. Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz","year":"2020","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0110","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","article-title":"Use of angiotensin II for post cardiopulmonary bypass Vasoplegic syndrome","volume":"108","author":"Evans","year":"2019","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0120","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0125","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0130","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0135","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI115881","article-title":"Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II","volume":"90","author":"Gibbons","year":"1992","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0008-6363(03)00498-X","article-title":"Cardiomyocyte apoptosis in hypertensive cardiomyopathy","volume":"59","author":"Gonzalez","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/HJH.0000000000000358","article-title":"Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension","volume":"33","author":"Gonzalez","year":"2015","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","article-title":"Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells","volume":"74","author":"Griendling","year":"1994","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.20050828","article-title":"Multiple organ infection and the pathogenesis of SARS","volume":"202","author":"Gu","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0160","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0009-9236(99)70111-6","article-title":"Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction","volume":"65","author":"Guazzi","year":"1999","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0170","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jir.2010.0073","article-title":"Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages","volume":"31","author":"Guo","year":"2011","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options","author":"Guzik","year":"2020","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0180","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/01.HYP.26.4.642","article-title":"Apoptosis in target organs of hypertension","volume":"26","author":"Hamet","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa329","article-title":"Is there an association between COVID-19 mortality and the renin-angiotensin system-a call for epidemiologic investigations","author":"Hanff","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1378\/chest.91.1.52","article-title":"Angiotensin converting enzyme in bronchoalveolar lavage in ARDS","volume":"91","author":"Idell","year":"1987","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0205","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: A nationwide population-based cohort study","author":"Jung","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0210","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/092986711796642562","article-title":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: Their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome","volume":"18","author":"Kaparianos","year":"2011","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0215","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0220","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2018.01.019","article-title":"Human coronavirus circulation in the United States 2014-2017","volume":"101","author":"Killerby","year":"2018","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0225","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1165\/rcmb.2006-0379TR","article-title":"The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis","volume":"37","author":"Konigshoff","year":"2007","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0230","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.metabol.2019.03.006","article-title":"Angiotensin-(1-7), Adipokines and inflammation","volume":"95","author":"Lelis","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13054-018-1967-3","article-title":"Vasoplegia treatments: the past, the present, and the future","volume":"22","author":"Levy","year":"2018","journal-title":"Critical Care (London, England)"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0245","doi-asserted-by":"crossref","first-page":"L178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0250","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Science China. Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: A review","author":"Madjid","year":"2020","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0260","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0265","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1164\/ajrccm.161.6.9907004","article-title":"Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor","volume":"161","author":"Marshall","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0270","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/thorax.55.2.143","article-title":"Adult familial cryptogenic fibrosing alveolitis in the United Kingdom","volume":"55","author":"Marshall","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0275","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/rccm.2108086","article-title":"Angiotensin converting enzyme insertion\/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome","volume":"166","author":"Marshall","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0280","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0290","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mvr.2010.12.003","article-title":"Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: Vessel, organ and species specificity","volume":"81","author":"Metzger","year":"2011","journal-title":"Microvascular Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0295","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2213-2600(20)30224-1","article-title":"SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors","volume":"8","author":"Milne","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0300","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1161\/01.CIR.102.16.2011","article-title":"Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury","volume":"102","author":"Orfanos","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","article-title":"Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: A positive feedback mechanism in the RAS","volume":"66","author":"Patel","year":"2014","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0310","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0315","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","article-title":"COVID-19, SARS and MERS: Are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clinical Microbiology and Infection\u202f: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0320","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0325","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0330","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","article-title":"Novel RAAS agonists and antagonists: Clinical applications and controversies","volume":"11","author":"Romero","year":"2015","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0335","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","article-title":"Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype","volume":"73","author":"Sadoshima","year":"1993","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0340","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jgs.16472","article-title":"COVID-19 and older adults: What we know","volume":"68","author":"Shahid","year":"2020","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0345","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.2353\/ajpath.2007.061205","article-title":"Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma","volume":"170","author":"Shen","year":"2007","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0350","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ajpath.2016.12.020","article-title":"p53 and miR-34a feedback promotes lung epithelial injury and pulmonary fibrosis","volume":"187","author":"Shetty","year":"2017","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0355","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/eurheartj\/ehaa408","article-title":"Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019","volume":"41","author":"Shi","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0360","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","author":"Shi","year":"2020","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0365","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and mas receptor axis in inflammation and fibrosis","volume":"169","author":"Simoese Silva","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0370","doi-asserted-by":"crossref","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: Evaluating the evidence","author":"Sriram","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0380","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/02770909909055418","article-title":"Effects of angiotensin-converting enzyme (ACE) inhibitors on oxygen radical production and generation by murine lung alveolar macrophages","volume":"36","author":"Suzuki","year":"1999","journal-title":"The Journal of Asthma"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0390","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2007.138","article-title":"Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats","volume":"19","author":"Tu","year":"2008","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0395","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.biocel.2011.11.019","article-title":"Angiotensin signalling in pulmonary fibrosis","volume":"44","author":"Uhal","year":"2012","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0400","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2459\/JCM.0000000000000989","article-title":"Fulminant myocarditis triggered by OC43 subtype coronavirus: A disease deserving evidence-based care bundles","volume":"21","author":"Veronese","year":"2020","journal-title":"Journal of Cardiovascular Medicine (Hagerstown, Md.)"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0405","first-page":"L885","article-title":"Angiotensin II induces apoptosis in human and rat alveolar epithelial cells","volume":"276","author":"Wang","year":"1999","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0410","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/sj.gt.3302294","article-title":"Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107628_bb0420","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0415","article-title":"Angiotensin converting enzyme 2: A double-edged sword","author":"Wang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0425","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/jcb.21248","article-title":"Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung","volume":"101","author":"Wiener","year":"2007","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0430","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist","volume":"225","author":"Wosten-van Asperen","year":"2011","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0435","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host & Microbe"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0440","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0445","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1254\/jjp.60.33","article-title":"Angiotensin II-induced pulmonary edema in a rabbit model","volume":"73","author":"Yamamoto","year":"1997","journal-title":"Japanese Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0450","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/aps.2009.114","article-title":"Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis","volume":"30","author":"Yan","year":"2009","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0455","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/HJH.0000000000001613","article-title":"Deletion of protein kinase B2 preserves cardiac function by blocking interleukin-6-mediated injury and restores blood pressure during angiotensin II\/high-salt-diet-induced hypertension","volume":"36","author":"Yang","year":"2018","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0460","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single-center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0465","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0470","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2006.11.020","article-title":"Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction","volume":"140","author":"Yao","year":"2007","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0475","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1210\/en.2006-0602","article-title":"Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase\/protein kinase B and adenosine 5\u2032-monophosphate-activated protein kinase signaling pathways","volume":"148","author":"Yuan","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0480","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: Acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Critical Care (London, England)"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0485","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00011-015-0805-1","article-title":"ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response","volume":"64","author":"Zhang","year":"2015","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0490","article-title":"Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0495","doi-asserted-by":"crossref","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0500","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0505","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/01.HYP.0000097603.55404.35","article-title":"Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats","volume":"42","author":"Zhao","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003950","article-title":"Deletion of the murine cytochrome P450 Cyp2j locus by fused BAC-mediated recombination identifies a role for Cyp2j in the pulmonary vascular response to hypoxia","volume":"9","author":"Zhou","year":"2013","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2020.107628_bb0515","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:06:28Z","timestamp":1759010788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":103,"alternative-id":["S0163725820301583"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107628","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107628"}}